NetworkNewsBreaks – Endonovo Therapeutics Inc.’s (ENDV) SofPulse(R) Reduces Opioid Prescriptions at New Hanover Regional Medical Center

November 6, 2019 09:28:46

Commercial-stage developer of innovative medical devices Endonovo Therapeutics (OTCQB: ENDV) was recently featured in a article by Jack Bailey titled, ‘Medical device lowers opioid prescriptions at NHRMC’. The article highlights ENDV’s noninvasive Electroceutical(R) therapeutic device, SofPulse(R). According to the article, surgeons at New Hanover Regional Medical Center are utilizing SofPulse(R) as an alternative to narcotics to treat patients’ pain. SofPulse(R) works by using electromagnetic waves to lower inflammation and accelerate the recovery process. NHRMC urologist Dr. Roc McCarthy pointed out there has been a 30%-40% decline in post-op narcotic prescriptions since they began using the device six months ago. “It’s just opening the door to a world of opportunity for people to come up and innovate other ways of decreasing the amount of pain that people are having,” Dr. Roc McCarthy stated in the article.

To view the full article, visit

About Endonovo Therapeutics

Endonovo Therapeutics is a commercial-stage developer of noninvasive, wearable Electroceuticals(R) therapeutic devices. The company’s current portfolio of commercial and clinical-stage wearable Electroceuticals(R) therapeutic devices addresses wound healing, pain, postsurgical pain and edema, cardiovascular disease, chronic kidney disease, and central nervous system (“CNS”) disorders including traumatic brain injury (“TBI”), acute concussions, post-concussion syndrome and multiple sclerosis. The company’s noninvasive Electroceutical(R) therapeutic device, SofPulse(R), which uses pulsed short-wave radiofrequency at 27.12 MHz, has been FDA cleared and CE marked for the palliative treatment of soft-tissue injuries and postoperative pain and edema and has CMS national coverage for the treatment of chronic wounds. The company’s current portfolio of preclinical-stage Electroceuticals(R) therapeutic devices addresses chronic kidney disease, liver-disease nonalcoholic steatohepatitis (NASH), cardiovascular and peripheral artery disease (PAD), and ischemic stroke. The company’s noninvasive, wearable Electroceuticals(R) therapeutic devices work by restoring key electrochemical processes that initiate anti-inflammatory and growth-factor cascades necessary for healing to occur. For more information, visit the company’s website at

NOTE TO INVESTORS: The latest news and updates relating to ENDV are available in the company’s newsroom at

About NetworkNewsWire

NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published:

NetworkNewsWire (NNW)
New York, New York
212.418.1217 Office